The mechanisms of resistance to second- and third-generation ALK inhibitors and strategies to overcome such resistance.

Anaplastic lymphoma kinase (ALK) inhibitors are widely known to contribute to the long-term survival of ALK-rearranged non-small cell lung cancer (NSCLC) patients. Based on clinical trial data, tre...